Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative therapies work by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to consumption. By triggering GLP-1 receptors in the pancreas, these substances boost insulin secretion and reduce glucago

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing variations in their